PITPNM2

Across TCGA pan-cancer cohorts, PITPNM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PITPNM2 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PITPNM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PITPNM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where PITPNM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	1.000	0.601	.018	10	view →
CCRCC	DFS	Quartile	II,III,IV	0.334	0.879	.028	7	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.399	.040	4	view →
PDAC	OS	Median	II,III,IV	0.740	0.895	.038	1	view →
LUAD	OS	Median	All	0.911	0.973	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PITPNM2–HNSC (OS)

Open the HNSC breakdown →